To investigate the potential use of IGF2BP1 as a diagnostic marker of ATC, two independent thyroid carcinoma validation cohorts, one previously assembled in-house tissue microarray (TMA I: 20 ATC, 147 tumor samples total and 108 paired NT samples) and a commercial tissue microarray (TMA II: 6 ATC, 70 tumor samples total, and 10 unpaired NT samples) were analyzed for IGF2BP1 protein expression by immunohistochemistry (Table 3). Here, IGF2BP1 is linked to neoplasm.